Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received a consensus rating of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $21.80.

Several brokerages have recently weighed in on CLBT. Needham & Company LLC reduced their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, DA Davidson upped their price objective on Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 6th.

Insider Transactions at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the sale, the chief financial officer owned 334,219 shares of the company’s stock, valued at $5,474,507.22. The trade was a 11.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 157,580 shares of company stock worth $2,471,488. 5.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cellebrite DI

A number of institutional investors have recently modified their holdings of the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its holdings in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the period. Advisory Services Network LLC purchased a new position in Cellebrite DI during the 3rd quarter worth $40,000. CWM LLC raised its position in Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares in the last quarter. Elevation Wealth Partners LLC bought a new stake in Cellebrite DI during the 2nd quarter valued at $44,000. Finally, First Horizon Corp lifted its holdings in shares of Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after buying an additional 2,337 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $15.90 on Thursday. Cellebrite DI has a 1 year low of $11.02 and a 1 year high of $19.98. The firm has a 50-day simple moving average of $14.55 and a two-hundred day simple moving average of $14.09. The company has a market cap of $3.97 billion, a P/E ratio of 56.79, a PEG ratio of 1.98 and a beta of 1.18.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.